Technical Analysis for BMEA - Biomea Fusion, Inc.

Grade Last Price % Change Price Change
F 15.77 -11.68% -2.09
BMEA closed down 11.68 percent on Monday, March 18, 2024, on 1.47 times normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline.
5 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
Fell Below 200 DMA Bearish 0.00%
Fell Below 50 DMA Bearish 0.00%
MACD Bearish Signal Line Cross Bearish 0.00%
20 DMA Support Bullish -11.68%
50 DMA Support Bullish -11.68%
Crossed Above 200 DMA Bullish -11.68%
MACD Bullish Signal Line Cross Bullish -11.68%
Pocket Pivot Bullish Swing Setup -11.68%
Volume Surge Other -11.68%

   Recent Intraday Alerts

Alert Time
Down 10% about 15 hours ago
60 Minute Opening Range Breakdown about 16 hours ago
Fell Below 10 DMA about 16 hours ago
Down 1 ATR about 16 hours ago
20 DMA Support about 17 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective irreversible inhibitor of MENIN, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was founded in 2017 and is based in Redwood City, California.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer

Is BMEA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Comments

T

TraderMike 12 months ago

I found this on the "Calm After Storm" scan today (I also like the NR7 & Doji).  These little biotechs are always interesting after having a big pop based on some good/promising news.  The standard plan seems to be to immediately issue a secondary offering -- which BMEA did.  So now I'm looking for it to climb back above that offering price of $30 and retest the March high.

0 Reply

View full discussion...

Indicators

Indicator Value
52 Week High 43.64
52 Week Low 8.125
Average Volume 997,964
200-Day Moving Average 17.45
50-Day Moving Average 16.70
20-Day Moving Average 16.76
10-Day Moving Average 16.35
Average True Range 1.53
RSI (14) 45.36
ADX 17.45
+DI 21.17
-DI 22.30
Chandelier Exit (Long, 3 ATRs) 14.75
Chandelier Exit (Short, 3 ATRs) 18.84
Upper Bollinger Bands 18.92
Lower Bollinger Band 14.61
Percent B (%b) 0.27
BandWidth 25.72
MACD Line -0.11
MACD Signal Line -0.05
MACD Histogram -0.0577
Fundamentals Value
Market Cap 562.9 Million
Num Shares 35.7 Million
EPS -3.33
Price-to-Earnings (P/E) Ratio -4.73
Price-to-Sales 0.00
Price-to-Book 3.18
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 18.96
Resistance 3 (R3) 19.31 18.60 18.43
Resistance 2 (R2) 18.60 17.79 18.43 18.25
Resistance 1 (R1) 17.18 17.29 16.83 16.83 18.07
Pivot Point 16.47 16.47 16.29 16.30 16.47
Support 1 (S1) 15.05 15.66 14.70 14.70 13.46
Support 2 (S2) 14.34 15.16 14.17 13.28
Support 3 (S3) 12.92 14.34 13.10
Support 4 (S4) 12.57